Reclassification of gastrointestinal mesenchymal tumors

##plugins.themes.academic_pro.article.sidebar##

Published Jan 19, 2016
Download
pdf
Vol. 93 No. 12 (2015): Issue Dec 2015

##plugins.themes.academic_pro.article.main##

Salma Kamoun
Issam M'sakni
Nada Mansouri
Basma Laabidi
Abdeljabbar Helali
Ahmed Nabil Gordah
Fathi Bougrine
Ammar Bouziani

Abstract

SUMMARY
Background: Gastrointestinal stromal tumors - commonly called GISTs - are rare; yet, they represent an important type of mensenchymal tumors arising within the gastrointestinal tract. The acronym GIST was introduced in 1998 to define a well established pathological entity which bears a highly specific marker called KIT (CD117). Scientific interest for these tumors in recent years is mainly due to the progress in identification by immunohistochemistry and the advent of targeted molecular therapy.
Aim: To reclassify mesenchymal tumors of the digestive tract using advanced immunophenotyping.
Methods: We examined the digestive tissue tumors operated at the Principal Military Hospital of Instruction of Tunis over a 19-year period from 1992 to 2011.
Results: We collected 22 cases of benign mesenchymal tumors of the digestive tract. Tumors were initially diagnosed as leiomyomas (4 cases), schwannomas (2 cases), gastrointestinal stromal tumors (14 cases), a leiomyoblastoma and a mesenchymal tumor with fusiform cells. The immunohistochemical study has allowed to correct some diagnoses and, in one case, the block has been exhausted. In total, we selected 18 cases of gastrointestinal stromal tumor, a tumors. The final diagnosis of GIST was confirmed by the positivity of C-kit or DOG1.
Conclusions: The combined use of C-kit and DOG1 ensures accurate diagnosis of GIST. The DOG1 has allowed us to detect the 3 stromal tumors negative for C-kit. This antibody has achieved a diagnostic gain of 15 %. The rate of GIST tumors labeled increased from 71 % to 86 % among mesenchymal tumors.

Keywords:

Mesenchymal tumor, stromal tumor, digestive tract, immunohistochemistry, KIT, Dog1.

##plugins.themes.academic_pro.article.details##

References

  1. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-80.
  2. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152:1259-69
  3. Nilsson B, Bümming P, Meisâ€Kindblom JM, et al. Gastrointestinal stromal tumors: The incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era. Cancer 2005; 103:821-9.
  4. Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Archiv 2001; 438:1-12.
  5. Fletcher CD, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Inter J Surg Pathol 2002; 10:81-9.
  6. Kang GH, Srivastava A, Kim YE, et al. DOG1 and PKC-θ are useful in the diagnosis of KIT-negative gastrointestinal stromal tumors. Mod Pathol 2011; 24:866-75.
  7. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol 2008; 32:210-8.
  8. Kang YN, Jung HR, Hwang I. Clinicopathological and immunohistochemical features of gastointestinal stromal tumors. Cancer Res Treat 2010; 42:135- 43.
  9. Gutierrez M, Dorronsoro M, Marco A, Pérez I, Villegas I, Virseda J. The role of the DOG1 antibody in the diagnosis of gastrointestinal stromal tumours- GIST. An Sist Sanit Navar 2011; 34:245-51.
  10. Trabelsi A, Mestiri S, Stita W, et al. Les tumeurs mésenchymateuses du tube digestif, apport de l'immunohistochimie. Ann Bio Clin 2007; 65:365-8.
  11. Lahmar Boufaoura A, Ben Salam S, Bouraoui S, et al. Révision de 32 tumeurs mésenchymateuses avec le CD117. Tun med 2009; 87:133-6.
  12. Bellil K, Bouraoui S, Chelly I, et al. Apport du CD117 dans le diagnostic des tumeurs conjonctives du tube digestif. Tun med 2005; 83:669-71.
  13. Giuly JA, Picand R, Giuly D, Monges B, Nguyen-Cat R. Von Recklinghausen disease and gastrointestinal stromal tumors. Am J Surg 2003; 185:86-7.
  14. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-25.
  15. Liegl-Atzwanger B, Fletcher JA, Fletcher CDM. Gastrointestinal stromal tumors. Virchows Arch 2010; 456:111-27.
  16. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004; 28:889-94.
  17. Debiec-Rychter M, Wasag B, Stul M et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004; 202:430-8.
  18. Lee CH, Liang C, Espinosa I. The utility of discovered on gastrointestinal stromal tumor 1 (DOG1) antibody in surgical pathology-the GIST of it. Adv Anat Pathol 2010; 17:222-32.
  19. Lopes LF, West RB, Bacchi LM, van de Rijn M, Bacchi CE. DOG1 for the diagnosis of gastrointestinal stromal tumor (GIST): Comparison between 2 different antibodies. Appl Immunohistochem Mol Morphol 2010; 18:333-7.
  20. Liegl B, Hornick JL, Corless CL, et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes. Am J Surg Pathol 2009; 33:437-46.
  21. Miettinen M, Wang ZF, Lasota J. DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors. A study of 1840 cases. Am J Surg Pathol 2009; 33:1401-7.
  22. Ríos-Moreno MJ, Jaramillo S, Pereira Gallardo S, et al. Gastrointestinal stromal tumors (GISTs): CD117, DOG-1 and PKCθ expression. Is there any advantage in using several markers? Pathol Res Pract 2012; 208:74- 81.
  23. Jarboui L, Daoud E, Ouled Hmeidi Y, et al. Imagerie en coupes des tumeurs stromales gastro-intestinales (GIST). J Radiol 2006:1466.
  24. Duffaud F, Blay J-Y. Gastrointestinal stromal tumors: biology and treatment. Oncology 2003; 65:187-97.
  25. Miettinen M, Sobin LH, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol 2000; 13:1134-42.
  26. Blackstein ME, Blay J-Y, Corless C, et al. Gastrointestinal stromal tumours: consensus statement on diagnosis and treatment. Canadian journal of gastroenterology 2006; 20:157.
  27. Gutierrez MR, Dorronsoro ML, Marco AM, Pérez IR, Villegas IA, Virseda JM. The role of the DOG1 antibody in the diagnosis of gastrointestinal stromal tumours-GIST. An Sist Sanit Navar 2010; 34:245-51.